- Home
- ACCS vs ONCY Comparison
ACCS vs ONCY Comparison
Compare ACCS & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACCS
- ONCY
- Stock Information
- Founded
- ACCS 1988
- ONCY 1998
- Country
- ACCS United States
- ONCY Canada
- Employees
- ACCS N/A
- ONCY N/A
- Industry
- ACCS Publishing
- ONCY Pharmaceuticals and Biotechnology
- Sector
- ACCS Consumer Discretionary
- ONCY Health Care
- Exchange
- ACCS Nasdaq
- ONCY Nasdaq
- Market Cap
- ACCS 46.0M
- ONCY 49.1M
- IPO Year
- ACCS N/A
- ONCY 1999
- Fundamental
- Price
- ACCS $12.05
- ONCY $0.69
- Analyst Decision
- ACCS Strong Buy
- ONCY Strong Buy
- Analyst Count
- ACCS 1
- ONCY 4
- Target Price
- ACCS $15.00
- ONCY $4.33
- AVG Volume (30 Days)
- ACCS 8.7K
- ONCY 1.4M
- Earning Date
- ACCS 08-07-2025
- ONCY 07-31-2025
- Dividend Yield
- ACCS N/A
- ONCY N/A
- EPS Growth
- ACCS N/A
- ONCY N/A
- EPS
- ACCS N/A
- ONCY N/A
- Revenue
- ACCS $22,961,000.00
- ONCY N/A
- Revenue This Year
- ACCS $7.67
- ONCY N/A
- Revenue Next Year
- ACCS N/A
- ONCY N/A
- P/E Ratio
- ACCS N/A
- ONCY N/A
- Revenue Growth
- ACCS 6.92
- ONCY N/A
- 52 Week Low
- ACCS $7.61
- ONCY $0.33
- 52 Week High
- ACCS $13.35
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- ACCS N/A
- ONCY 69.96
- Support Level
- ACCS N/A
- ONCY $0.56
- Resistance Level
- ACCS N/A
- ONCY $0.37
- Average True Range (ATR)
- ACCS 0.00
- ONCY 0.07
- MACD
- ACCS 0.00
- ONCY 0.04
- Stochastic Oscillator
- ACCS 0.00
- ONCY 83.26
About ACCS ACCESS Newswire Inc. Common Stock
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.